Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics to Announce Full-Year 2017 Financial Results on February 28, 2018
CRANBURY, N.J. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Wednesday, February 28, 2018 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2017 . The call will be hosted by John F.
View HTML
Toggle Summary Amicus Therapeutics Prices Underwritten Offering of Common Stock
CRANBURY, N.J. , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share. The gross proceeds from the offering to Amicus are expected to be $300 million, before deducting
View HTML
Toggle Summary Amicus Therapeutics Announces Public Offering of Common Stock
CRANBURY, N.J. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced it has commenced a $250 million underwritten public offering of its common stock. J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as joint lead book-running managers, Cowen and
View HTML
Toggle Summary Amicus Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference
CRANBURY, N.J. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley , Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the LEERINK Partners 7th Annual Global Healthcare Conference in New York, NY on
View HTML
Toggle Summary U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
Six-Month PDUFA Goal Date is August 13, 2018 CRANBURY, N.J. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the New Drug Application (NDA) for filing under priority review for the oral precision
View HTML
Toggle Summary Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium™
         Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Out to Month 12 Very Low Rate (
View HTML
Toggle Summary Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold™ (migalastat) for Fabry Disease in Canada
CRANBURY, N.J. , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that the Common Drug Review (CDR) has posted the Canadian Drug Expert Committee (CDEC)’s positive recommendation of Galafold™ (migalastat) for listing with provincial drug formularies.
View HTML
Toggle Summary Amicus Therapeutics Announces Presentations and Posters at 14th Annual WORLDSymposium™ 2018
CRANBURY, N.J. , Jan. 22, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that two oral presentations and seven posters highlighting its development programs for Lysosomal Storage Disorders will be included at the 14 th Annual WORLD Symposium™ 2018, to be held February
View HTML
Toggle Summary Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in Spain
CRANBURY, N.J. and MADRID, Spain , Jan. 17, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in Spain following final pricing and
View HTML
Toggle Summary Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance
             310+ People with Fabry Disease Treated with Reimbursed Galafold® at YE17 FY18 Galafold Revenue Guidance of $75M-$85M Regulatory Agreement on Comparability of 1,000L Scale Engineering Material for Pompe Additional Pompe Phase 1/2 Clinical Study Results to be Presented at WORLDSymposium™
View HTML